Skip to content
NewsBlazeAU – Lifestyle
Author:
Actinogen Medical
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
May 28, 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
April 1, 2026